ARTEMIDE-Lung04 Trial
Phase 3
830
about 5.6 years
18+
31 sites in DE, FL, GA +14
About this study
Researchers are testing whether rilvegostomig or pembrolizumab monotherapy is effective as a first treatment for people with advanced non-small cell lung cancer whose tumors have high levels of PD-L1. The trial will last 2062 days and involve approximately 830 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Pembrolizumab
- 2.Receive Rilvegostomig
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Overall Survival (OS), Progression-Free Survival (PFS)
Secondary: Duration of Response (DoR), Landmark Overall Survival (OS) rates, Landmark Progression-Free Survival (PFS) rates, Objective Response Rate (ORR), Patient-reported global health status (GHS)/quality of life (QoL), Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), Pharmakokinetics (PK) of rilvegostomig, Time to second progression or death (PFS2)
Oncology